The serum complement system is a major mediator of inflammation reactions. Two of the complement proteins, the third (C3) and fifth (C5) components, are precursors of potent phlogistic molecules, C3a and CSa. C5a has potent chemotactic activity and plays an active role in pulmonary inflammation. We present evidence suggesting that several complement proteins, including C5, are synthesized locally in the lung in alveolar type II epithelial cells. Lung tissue from normal mice synthesized and secreted C5 protein similar to the C5 protein in mouse serum, whereas lung tissue from C5-deficient mice did not. Lung tissues from both normal and C5-deficient mice synthesized C3. Rat lung tissue synthesized and secreted C5, as well as C2, C4, C3, and factor B. Cultures of type II cells (95% type II cells, 5% macrophages) regularly synthesized all these proteins. In contrast, cultures of macrophages alone synthesized large amounts of C2 and factor B, and in some experiments C3 and C4, but never C5. The C5 synthesized by the rat cells was slightly larger than serum C5 (200 kD compared with 180 kD) and was not processed to the two-chain molecule seen in serum. Rat lung tissue and purified type II cells contained C5 mRNA with the same molecular mass as the C5 mRNA in rat liver and in mouse lung and liver. Human type II cells also synthesized C5, as well as C2, C4, C3, and factor B. Human pulmonary macrophages synthesized only C2, factor B, and, in some experiments, C3. Synthesis of complement proteins in cells that line the alveolar wall may provide a local source of these proteins for inflammatory responses in the lung. Local synthesis of complement proteins could be regulated independently of the synthesis in the liver.
Introduction
The complement system, a set of 20 plasma proteins, is an effector of several functions associated with inflammation, immunologic regulation, and cytotoxicity (1) . Two of these proteins, the third (C3) and fifth (C5) components, are precursors of potent phlogistic molecules, C3a and COa. C5a has potent chemotactic activity (2) and has been implicated in the initiation of pulmonary inflammation in both animals and man. Direct instillation of C5a into the lungs of rabbits results in massive influx of neutrophils into the lungs (3) . In addition, mice that are congenitally deficient in C5 have markedly decreased and delayed inflammatory responses to a number of stimuli (4) (5) (6) . Transfusion of plasma from normal mice (containing C5) into the deficient animals before administration of the inflammatory stimulus restores the inflammatory response (5) . In addition, activation of C5 in man is associated with leukocyte-mediated pulmonary dysfunction (7) .
C5a can be generated from C5 by either the classical or the alternative complement activation pathways (1) . Although the liver is the major site of synthesis of the complement proteins (8, 9) , components of both activation pathways are produced locally in lung tissue, Cl in fibroblasts (10) , and C2, C4, C3, and factor B in macrophages (11) (12) (13) . Kreutzer and coworkers (14) have reported production of hemolytically active C5 in cultures of fetal lung cells and suggested that type II epithelial cells may be a site of C5 synthesis. The purpose of these studies was to investigate the source of C5 synthesis in lung tissue. We have used purified alveolar type II epithelial cells from humans and rats to study the synthesis ofindividual complement proteins in vitro. We report that both human and rat alveolar type II epithelial cells synthesize proteins in both the classical and alternative activation pathways, as well as C3 and C5. The local production of complement proteins may be important in pulmonary inflammation.
Methods

Reagents
Dulbecco's modified minimal essential medium (DMEM)' was purchased from M.A. Bioproducts, Walkersville, MD; DME 80-0072 (without methionine) from Gibco Laboratories, Grand Island, NY; and fetal bovine serum, penicillin, streptomycin, and L-glutamine from Flow Laboratories, McLean, VA. Albumin bovine crystallized, purity: 98% minimum, was purchased from ICN Nutritional Biochemicals, Cleveland, OH. Pepstatin A was purchased from Sigma Chemical Co., St. Louis, MO (15) . Anti-human C2 prepared in sheep was obtained from Seward Labs (London, England), IgG fractions of goat anti-human C3, factor B, and C4 from Atlantic Antibodies (Scarborough, ME), and goat antihuman C5 from Miles Scientific Div., Miles Labs Inc. (Naperville, IL). An MAb to human C5 was kindly provided by Dr. Patricia Giclas, National Jewish Center for Immunology and Respiratory Medicine. Since C5 and C3 are similar in size and subunit structure and purified preparations of C5 used for production of antibody can easily be contaminated with C3, specificity of the antisera for C5 was confirmed. For mouse C5, all three anti-C5 antisera detected protein in serum of normal, but not C5-deficient, mice. For rat C5, the antisera precipitated a rat serum protein ofthe size and subunit structure characteristic for serum C5. For human C5, precipitation of labeled C5 from lysate and extracellular medium of HepG2 cells biosynthetically labeled with [35S]methionine was blocked with purified human C5, whereas the purified C5 had no effect on the precipitation of C3 by the goat antihuman C3.
Materials for stimulation of complement synthesis in rat type II cells were obtained as follows. Rat 
Cells
Rat type II cells. Type II cells were obtained from specific pathogenfree male Sprague-Dawley rats by a modification of the elastase method described by Dobbs et al. (16) . Briefly, after killing, a tracheostomy was performed and the pulmonary vasculature was perfused with HBSS. The lungs were excised and lavaged eight times to remove as many of the alveolar macrophages as possible. The lungs were then instilled via the trachea with a fluorocarbon-albumin emulsion as a phagocytosible article, incubated in a saline waterbath at 37°C for 20 min, and lavaged eight additional times to remove any remaining macrophages. EGTA was added for the last two lavages to loosen some ofthe intercellular junctional complexes, and elastase was then instilled via the airway. After a second incubation at 37°C for 20 min, the lungs were removed, minced, and a single cell suspension was obtained by filtration through nylon mesh. The cells were separated on a discontinuous metrizamide density gradient and then plated on tissue culture plastic in 10% FCS for 24 h before nonadherent cells were removed by washing. Type II cells were identified by the modified Papanicolaou stain (17) , the tannic acid and polychrome stain (18) , and alkaline phosphatase staining (19) . Quantitation was done with alkaline phosphatase, but is essentially identical to the other procedures. These stains are negative for macrophages. The adherent cells were 94±2% type II cells (Table I) .
Rat type II cells were also prepared after initial adherence of pulmonary macrophages on dishes coated with rat IgG (20) . Plates for adherence of the macrophages from the cell suspension were prepared by incubating 35-mm bacteriologic plastic dishes each with 1 ml of rat IgG solution (Sigma Chemical Co.; 500 Ag/ml in 50 mM Tris-base, pH 9.5) for 3 h at 22°C, and then washing five times with phosphate-buffered saline and once with DMEM. After incubation of the lung with elastase (20) , the cells were filtered through nylon mesh and centrifuged at 130 g for 8 min at 4°C. The cell pellet was resuspended gently at 1.2-1.9 X 106 cells/ml in DMEM containing 2 mM L-glutamine, 100 U/ml penicillin, 100 ,ug/ml streptomycin, 10 Ag/ml gentamicin sulfate, and 2.5 yg/ml amphotericin B without serum. 2 ml of the cell suspension was added to each 35-mm IgG-coated dish and allowed to adhere for 1 h at 37°C and 10% CO2. The plates were then gently tipped back and forth three times to free loosely adherent type II cells while not detaching adherent macrophages. The unattached cells were supplemented with 10% fetal bovine serum and transferred to 35-mm tissue culture dishes. Type II cells were allowed to adhere during a 24-h incubation at 37°C in 10% CO2.
The rat type II cells prepared by both the standard elastase method (16) and the alternative (IgG adherence) method (20) had similar capacities to produce complement proteins. Therefore, the results of experiments with these two preparation procedures were combined.
Human type II cells. Type II cells were isolated from resected human lung by the method described by Robinson et al. (21) . Specimens were obtained from patients undergoing lobectomy or pneumonectomy for cancer. Pathologists removed the tumor, and a piece of adjacent lung encased in pleura was used for the isolation. Airways of resected lung were cannulated and the lungs lavaged with HBSS and then instilled with pancreatic elastase. After digestion, the lungs were minced and the dissociated cells were isolated by filtration through nylon mesh and then separated on a metrizamide density gradient. The macrophages were removed by adherence to tissue culture plastic for 90 min. The nonadherent type II cells were replated on culture dishes coated with extracellular matrix from bovine endothelial cells (22) and allowed to adhere for 24 h before the cells were washed. The adherent cells were 89±4% type II cells.
Rat pulmonary macrophages. Macrophages were obtained as a byproduct of the rat type II cell preparations in one of two ways. First, bronchoalveolar cells from the initial lavage after excision of the lungs were collected by centrifugation, washed, and resuspended in DMEM without serum for adherence on tissue culture plastic dishes. In most experiments, 1 X 106 were plated per 35-mm dish. After the 2-h adherence period, the cells were 80% confluent and numbered -4 X I05/ dish. These cells were > 99% macrophages as judged by nonspecific esterase (positive for macrophages) (23) and alkaline phosphatase * Results presented as means of results from the individual experiments. Labeled proteins were immunoprecipitated, separated by SDS-PAGE, and identified with fluorography. Slices containing the specific proteins were removed from the gel, digested, and counted after addition of scintillation fluid (radioactivity in slices without specific proteins were subtracted as background). Before immunoprecipitation, an aliquot of the sample was removed for determination of the radioactivity incorporated into TCA-precipitable protein.
staining (positive for type II cells and negative for macrophages) (19) ( Table I ).
In the second method, cells that were adherent on IgG-coated bacteriologic plastic culture dishes after the 1-h adherence step for the type II cell isolation were washed and cultured in medium containing 10% FCS for two more hours. These cells were 95±2% macrophages, with the remaining cells being type II cells (Table II) . The proportions of interstitial and bronchoalveolar macrophages were not determined.
Human pulmonary macrophages. Macrophages were obtained by two separate methods. Alveolar macrophages were obtained from smokers without active lung disease who were lavaged using standard techniques as controls for the Specialized Center of Research interstitial lung disease project at the National Jewish Center. Cells from the fifth or sixth lavage (50 ml) were pelleted (1,000 rpm, 4VC), washed once in HBSS, and resuspended in DMEM without serum. The cells were adhered to tissue culture plastic dishes (4 X 106 cells in 1 ml per 35-mm dish) for 2 h before washing. The adherent cells were > 99% macrophages (Table I) .
Pulmonary macrophages were also obtained as a byproduct of the type II cell preparation. Cells that were adherent on IgG-coated bacteriologic plastic culture dishes were washed and cultured in medium containing 10% FCS for two more hours. These cells were > 99% macrophages (Table II) . As with the rat macrophages obtained by this method, the proportions of interstitial and bronchoalveolar macrophages were not determined.
Minced lung tissue. Whole mouse and rat lungs were finely minced with a curved scissors, washed twice in HBSS, and divided into 50-mg portions, each ofwhich was resuspended in 0.5-ml portions oflabeling media. 
Biosynthetic labeling and immunoprecipitation
Immediately after the adherence periods, the cells were washed to remove conditioned medium and cultured for 2 h in 1.0 ml methionine-free medium containing 500 uCi [35S]methionine (24, 25) , except that the labeling medium contained protease inhibitors (10% dialyzed heat-inactivated FCS, 1 mg/ml soybean trypsin inhibitor, and 100
,gg/ml pepstatin A) to prevent cleavage of the proteins after secretion.
The extracellular medium was removed and the cells were washed twice in PBS (pH 7.4) and lysed by freeze-thaw in PBS containing protease inhibitors (10 mM EDTA and 2 mM PMSF in addition to soybean trypsin inhibitor and pepstatin A) and detergents (0.5% Triton-X 100 and 0.25% sodium desoxy cholate). The intracellular lysates were processed for immunoprecipitation by clarification (10,000 g for 15 min) and preabsorption with the formalin-fixed S. aureus for 60 min at 4VC (25) . Samples were immunoprecipitated by addition of excess monospecific antibody, incubation overnight at 40C, and addition of formalin-fixed S. aureus for 60 min at 4VC. The Staph protein A-antibody-antigen complexes were washed and then dissociated by heating (boiling) in Laemmli sample buffer (pH 6.8) and the immunoprecipitates subjected to SDS-PAGE. The resulting gels were fixed, impregnated with En3Hance, dried, and exposed at -70°C to Kodak XAR-5 film. Samples were sequentially immunoprecipitated for the various proteins by preclearing with additional formalin-fixed S. aureus and then reimmunoprecipitated for the different antigens using the appropriate monospecific antibody. C5 was always the first antigen precipitated to avoid possible interference of residual C3-anti-C3 complexes with the C5 signal. Incorporation of [35S]methionine into individual immunoprecipitated proteins was determined in gel slices after digestion with 15% hydrogen peroxide for 16 h and addition of ScintiVerse II (Fisher Scientific Co., Fair Lawn, NJ) (24, 25) ; the radioactivity in the gel slices was adjusted for the amount of total protein synthesized under the specific conditions, as determined by precipitation of aliquots of the lysates with 10% TCA (25) . Preliminary experiments demonstrated that incorporation of [35S]methionine into both total protein and specific complement proteins was dependent upon concentration of radiolabeled amino acid from 100 to 900 MCi/ml and was linear with time of culture up to 2 h.
RNA analysis
Total cellular RNA was prepared from frozen, pulverized organs or from washed tissue culture cells by cesium chloride gradient ultracentrifugation after lysis in 4 M guanidinium thiocyanate (26) . Poly A+ RNA was purified from 100 jig total cellular RNA using oligo-dT)-cellulose (27) and subjected to Northern analysis using mouse C5 cDNA (28) radiolabeled with 32P by nick-translation.
Results
Synthesis ofcomplement proteins in mouse and rat lung tissue.
Minced lung tissue from normal mice synthesized and secreted CS. The intracellular proCS was a single chain molecular mass of 180 kD and the extracellular material was a two-chain molecule with an alpha chain of 1 7 kD and a beta chain of 84 kD (Fig. 1) proteins precipitated from rat serum. The C5 had a molecular mass of 200 kD, slightly larger than the serum molecule, which is -180 kD. In addition, the C5 protein secreted by the cells did not reduce into the alpha and beta chains characteristic of C5 from mouse, rat, and human sera and the C5 secreted from the mouse lung cells (Fig. 1) . Minced whole lungs from rats in both specific pathogen-free and open colonies synthesized this single chain extracellular C5 molecule. Rat lung tissue contained C5 mRNA with the same molecular mass as the C5 mRNA in rat liver and in mouse liver and lung (Fig. 3) . For both the mouse and rat, the amount of C5 mRNA in the lung was much less than in the liver.
Synthesis ofcomplement proteins in specific rat lung cells.
Because procedures for the isolation of type II cells from mice are not available, synthesis of complement proteins in specific lung cells was studied only in rats and humans. The complement proteins synthesized in rat type II cells are shown in Fig.  2 . These cells synthesized C2, factor B, and C5 in each of 10 separate experiments, C4 in 8 of 10 experiments, and C3 in 9 of 10. The C5 synthesized and secreted by the purified type II cells was identical to the material from the minced lung tissue. In addition, the type II cells contained C5 mRNA (data not shown). Analysis of radioactivity in specific gel slices indicated that factor B and C3 were the most prevalent proteins synthesized (Table I) .
Because the rat type II cell cultures contained 4-8% pulmonary macrophages, experiments were designed to test the possibility that these contaminating macrophages were responsible for the complement synthesis in the type II cell cultures. Rat bronchoalveolar macrophages synthesized much more C2 and factor B than the type II cells (Table I) Figure 3 . Analysis of C5 mRNA in lung tissue from a normal, C5-sufficient mouse and a specific-pathogen free rat. Poly A+ RNA was extracted using oligo (dT)-cellulose from equal amounts of total cellular RNA (100 Mg) from liver and lungs of the two animals and subjected to Northern analysis using a 32P-nick translated mouse C5 cDNA. The hybridized Northern blot exposed to x-ray film for 18 h demonstrated a single species of C5 mRNA (-6.0 kD) in all four tissues, although the signal for the rat lung was faint. The signal for the C5 mRNA in rat lung after S d exposure is shown in the insert. of C4 and C5 was not detected in any of the experiments. The overall metabolic activity ofthe bronchoalveolar macrophages was similar to the activity of the pulmonary macrophages obtained from adherence of cells in elastase-digested lung to IgG-coated plates (incorporation of [35S]methionine into TCA-precipitable protein was 40 cpm/cell, range in four experiments).
Synthesis of complement proteins in human lung cells.
Type II cells were obtained from three patients undergoing lobectomy for carcinoma, and purified by adherence to bovine endothelial cell extracellular matrix (21) . Similar to the results with the rat type II cells, the human cells synthesized C2, C4, factor B, C3, and C5 proteins (Fig. 4) . These proteins had the same size and subunit composition as the proteins in human serum. Specifically, the C5 had a molecular mass of 180 kD intracellularly and 126 and 78 kD for the extracellular alpha and beta chains, respectively. These results were similar to those of the alpha and beta chains of C5 purified from serum (120 and 73 kD) and C5 synthesized by HepG2 cells (125 and 75 kD). Factor B and C3 were the most prevalent of the five complement proteins synthesized in the human type II cells (Table I) .
In one experiment, type II cells and pulmonary macrophages obtained from a single donor were studied to determine if the contaminating macrophages were responsible for the (29) . The identity of the molecule synthesized by the rat type II cells as C5 was supported by its immunoprecipitation with four separate anti-C5 antisera, including an anti-mouse C5 produced in C5-deficient mice, and the presence of C5 mRNA in both whole rat lung tissue and in rat type II cells. Finally, minced lung tissue from normal, but not C5-deficient, mice synthesized and secreted a C5 molecule characteristic of serum C5. The C5 protein synthesized but not processed and secreted by the deficient cells has also been noted by Ooi and Colten (30) .
Preliminary studies have indicated that the capacity of rat type II cells to synthesize complement proteins is increased by lymphokines and LPS. These data suggest that interactions of mediators produced in the lung during inflammation with the complement producing cells in the lung may provide a mechanism for regulation of production of complement proteins in the lung independent from regulation in the liver. This hypothesis is supported by the findings of Cole and co-workers, demonstrating differences in rates of synthesis of complement proteins in bronchoalveolar macrophages as compared with rates in monocytes and macrophages derived from other tissue sites (31) , and by studies by Cole et al. (32) indicating that changes in the biosynthesis of complement in bronchoalveolar macrophages were not predicted by levels of serum complement.
Because of the importance of C5 in the mediation of inflammation, several authors have studied its site of synthesis.
The hepatocyte is a site of C5 synthesis in the mouse, guinea pig, and human (9) . Identification of other cell types responsible for C5 synthesis in these species has been controversial. Studies with fetal tissues demonstrated C5 production by a wide variety of tissues, suggesting that C5 is produced by a widely distributed cell type (33). Peritoneal macrophages synthesized C5 in the mouse (29) , but evidence for active synthesis ofC5 in guinea pig peritoneal macrophages could not be demonstrated (34) . In the human, Whaley reported that peripheral blood monocytes incorporated radiolabeled amino acids into a protein that precipitated with antiserum to C5 in Ouchterlony analysis (35) , but other investigators could not detect C5 protein with the expected size and subunit composition (36) or C5 mRNA (Strunk, R. C., and F. S. Cole, unpublished observations) in these cells. Several studies have suggested that cells in the lung synthesize C5. Kolb et al. noted that C5/albumin ratios in lavage fluids were 3.5-fold higher than the corresponding ratios in matched serum samples, suggesting that the protein was synthesized, at least in part, by cells in the lung (37) . Kreutzer and co-workers (14) have reported production of hemolytically active C5 in cultures of fetal lung cells and suggested that the type II epithelial cell may be a site ofsynthesis of C5. Previous studies of complement synthesis in cells isolated from the lung have been confined largely to bronchoalveolar lavage macrophages, which synthesize C2 and C4 in guinea pigs (12) and C2, factor B, and C3 in humans (11) . Although several authors have suggested that the alveolar macrophage may be a site of synthesis of C5, synthesis of this protein could not be demonstrated in human alveolar macrophages from either normal subjects or patients with a variety of pulmonary diseases (1 1).
In our experiments, bronchoalveolar lavage macrophages from four adult smokers without lung disease synthesized large amounts of C2, less factor B, and in one experiment, C3, similar to the findings of Cole et al. (1 1) . The data from the experiments with rat bronchoalveolar lavage macrophages were similar to those with human cells, except that the rat cells synthesized much more C2 and factor B. Although these differences may be species specific, they may also be due to the environment of the cells and differences in the overall capacity of the cells to function: the human cells contained large numbers of carbon particles related to the smoking habits of the donors, and the rat cells did not contain these foreign particles.
Alveolar type II epithelial cells play an essential physiologic role in the alveolus by synthesizing and secreting surface-active material, by restoring the alveolar epithelium after damage to type I cells, and by transepithelial solute transport (38) . Although type II cells secrete a variety ofproteins, the function of many of these proteins are not known. The localization of synthesis of several complement proteins to the type II cell extends the spectrum of the functions of these cells. Since human tissue is relatively unavailable and its exposure to inflammatory stimuli (both type and duration) is usually poorly defined, use of rat lung cells could provide a model for more detailed study ofthe regulation ofcomplement proteins during pulmonary inflammation.
